New hope for BRCA breast cancer: could cisplatin beat standard chemo?
NCT ID NCT01670500
First seen May 17, 2026 · Last updated Jun 19, 2026 · Updated 6 times
Summary
This study tested whether cisplatin, a platinum-based chemo, works better than the standard doxorubicin/cyclophosphamide (AC) combo in women with newly diagnosed breast cancer who carry a BRCA mutation. 118 participants received either cisplatin or AC before surgery. The main goal was to see which treatment led to a higher rate of complete tumor disappearance (pathologic complete response).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
Sibley Memorial Hospital
Washington D.C., District of Columbia, 20016-2698, United States
-
Smilow Cancer Hospital Care Center at Derby
Derby, Connecticut, 06418, United States
-
Smilow Cancer Hospital Care Center at Guilford
Guilford, Connecticut, 06437, United States
-
St. Francis Hospital and Medical Center
Hartford, Connecticut, 06105, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
Women and Infants Hospital
Providence, Rhode Island, 02905, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cisplatin, Doxorubicin, Cyclophosphamide
What this could lead to
If cisplatin works better, it could offer a more effective chemotherapy option for women with BRCA-related breast cancer.
What could go wrong
This is a small Phase 2 trial, so results may not apply to all patients. Cisplatin also has side effects like kidney damage and nerve issues.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.